Company Filing History:

14 out of 6,662

Hoechst Aktiengesellschaft

patents

1 out of 260

Cassella Aktiengesellschaft

patents

Years Active: 1989-1998

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5721244 - Combination of angiotensin-converting enzyme inhibitors with calcium (1998-02-24),

2. 5500434 - Combination of angiotensin-converting enzyme inhibitors with calcium (1996-03-19),

3. 5231084 - Compounds having a cognition adjuvant action, agents containing them, (1993-07-27),

4. 5185324 - Enzyme-inhibiting amino acid derivatives, a process for the preparation (1993-02-09),

5. 5116835 - Enzyme-inhibiting urea derivatives of dipeptides, a process for the (1992-05-26),

6. 5114962 - New amino acid esters, a process for their preparation, medicaments (1992-05-19),

7. 5098910 - Combination of angiotensin-converting enzyme inhibitors with calcium (1992-03-24),

8. 5091427 - Piperazinediones having a psychotropic action (1992-02-25),

9. 5068242 - Pyrrolidine-2-carboxylic acid derivatives and their use for psychotropic (1991-11-26),

10. 5055483 - Novel amino acid glycerides, learning medicaments containing them and (1991-10-08),

11. 5043346 - Amino acid esters, pharmaceuticals containing them, and the use thereof (1991-08-27),

12. 4999370 - Compounds with a psychotropic action, agents containing them, and the (1991-03-12),

13. 4933346 - Diarylalkyl piperazine derivatives, a process for their preparation, (1990-06-12),

14. 4918073 - Diarylalkyl-substituted alkylamines and medicaments containing them (1990-04-17),

15. 4845099 - Tetrahydroquinoline derivatives, their use and pharmaceutical (1989-07-04),

Title: Wolfgang Ruger: A Pioneer in Medicinal Chemistry

Introduction

Wolfgang Ruger, based in Kelkheim, Germany, is a prolific inventor recognized for his contribution to medicinal chemistry. With a remarkable portfolio of 15 patents, Ruger has made significant strides in the development of innovative therapies that benefit healthcare.

Latest Patents

Among Ruger’s latest innovations are two notable patents that focus on the combination of angiotensin-converting enzyme inhibitors with calcium antagonists. The inventions relate to these combinations, highlighting processes for their preparation and their application as effective medicaments. Such advancements have the potential to enhance treatments for various health conditions, demonstrating Ruger's commitment to improving patient outcomes.

Career Highlights

Ruger’s career boasts substantial experience in influential companies, including Hoechst Aktiengesellschaft and Cassella Aktiengesellschaft. His tenure at these organizations has equipped him with the knowledge and expertise necessary to contribute to the field of medicinal chemistry effectively.

Collaborations

Throughout his career, Wolfgang Ruger has collaborated with esteemed colleagues, including Hansjorg Urbach and Franz Hock. These partnerships have fostered a collaborative environment, leading to innovative solutions and advancements in pharmaceutical research.

Conclusion

Wolfgang Ruger's contributions to the field of medicinal chemistry through his patents and collaborative efforts stand as a testament to his dedication as an inventor. His work not only reflects his expertise but also underscores the importance of innovation in improving health care. As he continues to develop new solutions, Ruger remains a vital figure in the ongoing advancement of medicinal therapies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com